Integrated DNA Technologies Introduces New HIV Panel to Advance Virology Research
2024年6月24日 - 9:50PM
ビジネスワイヤ(英語)
xGen™ HIV Amplicon Panel provides a
single-tube, 2.5-hour workflow designed to enable detection down to
1,000 viral genome copies
Global genomics solutions provider, Integrated DNA Technologies
(IDT), is bringing a new solution to address challenges researchers
face in accelerating Human Immunodeficiency Virus (HIV) drug
discovery and research. The company announced availability of the
xGen HIV Amplicon Panel consisting of primers designed to cover
99.3% of the HIV genome. Powered by IDT’s xGen Amplicon Technology,
the HIV panel provides a single-tube, two-step PCR amplification
workflow that uses overlapping primer sets to obtain high levels of
genome coverage from as low as 1,000 double-stranded viral genome
copies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240624954973/en/
IDT's new HIV Panel designed to advance
virology research provides a single-tube, 2.5-hour workflow to
enable detection down to 1,000 viral genome copies. (Photo:
Business Wire)
“This launch represents one of the many ways IDT is continuing
to innovate on its NGS portfolio, comprised of stand-alone library
preparation, target enrichment, and normalization chemistries, as
well as connected NGS solutions, to support researchers exploring
viral evolution, epidemiological studies, drug resistance
mechanisms and drug development research,” said Steven Henck, PhD,
Vice President, R&D at Integrated DNA Technologies. “While the
scientific community has learned a lot about HIV and the disease it
causes, continued research is needed to help the millions of people
whose health continues to be threatened by the global HIV/AIDS
pandemic. We believe our xGen HIV Amplicon Panel provides an
accessible option for researchers and will be foundational to
unlocking future discoveries and advancing HIV research.”
IDT’s xGen HIV Amplicon Panel offers a streamlined workflow that
goes from sample to sequencer in 2.5 hours with up to 1536 unique
dual indexing primers (UDIs) for multiplexed sequencing. This
predesigned xGen Amplicon Panel built with xGen Amplicon Technology
includes amplicon tiling and creation of super amplicons to ensure
comprehensive genome coverage across existing variant genomes and
provide resistance to future viral mutations that may fall within a
priming site, thus enabling future identification of novel
variants.
To learn more or order IDT’s xGen HIV Amplicon Panel, visit
idtdna.com/ngsHIV.
About IDT
For more than 35 years, Integrated DNA Technologies, Inc.
(IDT) has empowered genomics laboratories with an
oligonucleotide manufacturing process unlike anyone else in the
industry, featuring the most advanced synthesis, modification,
purification, and quality control capabilities available. Since its
founding in 1987, IDT has progressed from a leading oligo
manufacturer to a genomics solutions provider supporting key
application areas such as next generation sequencing, CRISPR genome
editing, synthetic biology, digital PCR, and RNA interference. IDT
manufactures products used by scientists researching many forms of
cancer and most inherited and infectious diseases.
Seeking to fulfill its mission of accelerating the pace of
genomics, IDT acquired Archer™ NGS Research Assays in December
2022. When combined with its existing solutions, the expanded
portfolio helps realize the shared vision of enabling researchers
to rapidly move from the lab to life-changing advances.
IDT’s infrastructure supports customers around the globe with
its manufacturing headquarters situated in Coralville, Iowa, USA,
with additional manufacturing sites in San Diego, California, USA;
Boulder, Colorado, USA; Research Triangle Park, North Carolina,
USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore.
IDT is proud to be part of Danaher. Danaher’s science and
technology leadership puts IDT’s solutions at the forefront of the
industry, so they can reach more people. Being part of Danaher
means we can offer unparalleled breadth and depth of expertise and
solutions to our customers.
Together with Danaher’s other businesses across Biotechnology,
Diagnostics and Life Sciences, we unlock the transformative
potential of cutting-edge science and technology to improve
billions of lives every day.
For more information about IDT, visit www.idtdna.com and follow
the company on LinkedIn, X, Facebook, YouTube, and Instagram.
Disclaimer: RUO — For research use only. Not for use in
diagnostic procedures. Unless otherwise agreed to in writing,
IDT does not intend these products to be used in clinical
applications and does not warrant their fitness or suitability for
any clinical diagnostic use. RUO24-2923_001
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240624954973/en/
Kristina Sarenas Director of PR 800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA) idtpr@idtdna.com